Key result
Higher PENK levels were independently associated with an increased risk of kidney function deterioration (OR 1.29; 95% CI 1.02-1.65 per doubling) and mortality in patients with heart failure.
Why the study?
PENK has been linked to heart failure severity and renal dysfunction, leading investigators to hypothesize that it could be associated with kidney function deterioration and serve as a novel renal marker in heart failure.
Is elevated proenkephalin (PENK) associated with deterioration of kidney function and mortality in patients with heart failure?
Cohort (n=3,883)
Yes
Is elevated proenkephalin (PENK) associated with deterioration of kidney function and mortality in patients with heart failure?
Odds Ratio: 1.29 (95% CI 1.02–1.65)
p-value: p=0.038
Elevated proenkephalin (PENK) levels in heart failure patients are associated with more severe disease, worsening renal function, and increased mortality, suggesting a role as a novel cardiorenal biomarker.
May refine HF risk stratification; hypothesis-generating and should not yet change practice.
BACKGROUND: PENK (proenkephalin) is a stable surrogate for enkephalins, endogenous opioid peptides, which exert cardiodepressive effects and improve renal function. PENK has been associated with heart failure (HF) severity and renal dysfunction. We therefore hypothesized that PENK could be associated with deterioration of kidney function and could have a role as a novel renal marker in HF. METHODS AND RESULTS: In 2180 patients with HF of a large multicenter cohort (BIOSTAT-CHF [A Systems Biology Study to Tailored Treatment in Chronic Heart Failure]), the relationship between PENK and clinical variables, plasma and urinary biomarkers, and clinical end points was established. Data were validated in a separate cohort of 1703 patients with HF. PENK was elevated (>80 pmol/L, 99th percentile) in 1245 (57%) patients. Higher PENK was associated with more advanced HF and glomerular and tubular dysfunction. The strongest independent predictor of PENK was estimated glomerular filtration rate. Others were plasma NGAL (neutrophil gelatinase-associated lipocalin) and NT-proBNP (N-terminal pro-B-type natriuretic peptide; all P<0.001). Using correlation heatmaps and hierarchical cluster analyses, PENK clustered with estimated glomerular filtration rate, creatinine, NGAL, galectin-3, and urea. Higher PENK was independently associated with increased risk of deterioration of kidney function between baseline and 9 months (odds ratio, 1.29 [1.02-1.65] per PENK doubling; P=0.038; defined as >25% decrease in estimated glomerular filtration rate) and mortality (hazard ratio, 1.23 [1.07-1.43] per doubling; P=0.004). Analyses in the validation cohort yielded comparable findings. CONCLUSIONS: Higher PENK levels are associated with more severe HF, with glomerular and tubular renal dysfunction, with incidence of a deterioration of kidney function, and with mortality. These findings suggest that the opioid system might be involved in deteriorating kidney function in HF.
No takes yet. Share an insight, caveat, or question.
Emmens et al. (2019) conducted a cohort in Heart failure (n=3,883). PENK (proenkephalin) levels was evaluated on Deterioration of kidney function between baseline and 9 months (>25% decrease in estimated glomerular filtration rate) (OR 1.29, 95% CI 1.02-1.65, p=0.038). Higher PENK levels were independently associated with an increased risk of kidney function deterioration (OR 1.29; 95% CI 1.02-1.65 per doubling) and mortality in patients with heart failure.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: